Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Camillo Porta

Showing results (321-330 of 388) with videos related to

Pageof 39
Sort By:
Frontiers in Oncology|September 4, 2023
Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib armsViktor Grünwald, Thomas Powles, Masatoshi Eto, et al.
Targeted Oncology|August 10, 2022
Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination TherapiesMatteo Santoni, Javier Molina-Cerrillo, Zin W Myint, et al.
Plos One|April 18, 2015
The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?Francesco Pantano, Matteo Santoni, Giuseppe Procopio, et al.
Future Oncology (London, England)|March 20, 2014
Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community settingGiuseppe Procopio, Lisa Derosa, Angela Gernone, et al.
Clinical Genitourinary Cancer|January 8, 2026
Attrition Rates in Metastatic Renal Cell Carcinoma (mRCC) Following First Line Immunotherapy-Based Treatment: Results From the International mRCC Database Consortium (IMDC)Audreylie Lemelin, Martin Zarba, Kosuke Takemura, et al.
JAMA Oncology|September 1, 2022
Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical TrialNizar M Tannir, Neeraj Agarwal, Camillo Porta, et al.
European Urology Oncology|February 11, 2020
Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumFrede Donskov, Wanling Xie, Anders Overby, et al.
Oncotarget|March 31, 2016
Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinomaDaniele Santini, Matteo Santoni, Alessandro Conti, et al.
European Urology Oncology|April 4, 2024
Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 StudyFrancesco Massari, Veronica Mollica, Ondrej Fiala, et al.
European Urology Oncology|August 15, 2019
Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumJeffrey Graham, J Connor Wells, Frede Donskov, et al.
Pageof 39

Showing results (321-330 of 388) with videos related to

Sort By:
Pageof 39
Frontiers in Oncology|September 4, 2023
Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib armsViktor Grünwald, Thomas Powles, Masatoshi Eto, et al.
Targeted Oncology|August 10, 2022
Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination TherapiesMatteo Santoni, Javier Molina-Cerrillo, Zin W Myint, et al.
Plos One|April 18, 2015
The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?Francesco Pantano, Matteo Santoni, Giuseppe Procopio, et al.
Future Oncology (London, England)|March 20, 2014
Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community settingGiuseppe Procopio, Lisa Derosa, Angela Gernone, et al.
Clinical Genitourinary Cancer|January 8, 2026
Attrition Rates in Metastatic Renal Cell Carcinoma (mRCC) Following First Line Immunotherapy-Based Treatment: Results From the International mRCC Database Consortium (IMDC)Audreylie Lemelin, Martin Zarba, Kosuke Takemura, et al.
JAMA Oncology|September 1, 2022
Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical TrialNizar M Tannir, Neeraj Agarwal, Camillo Porta, et al.
European Urology Oncology|February 11, 2020
Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumFrede Donskov, Wanling Xie, Anders Overby, et al.
Oncotarget|March 31, 2016
Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinomaDaniele Santini, Matteo Santoni, Alessandro Conti, et al.
European Urology Oncology|April 4, 2024
Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 StudyFrancesco Massari, Veronica Mollica, Ondrej Fiala, et al.
European Urology Oncology|August 15, 2019
Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumJeffrey Graham, J Connor Wells, Frede Donskov, et al.
Pageof 39